PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MRNA vs. JNJ
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between MRNA and JNJ is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

MRNA vs. JNJ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and Johnson & Johnson (JNJ). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
-70.57%
-1.32%
MRNA
JNJ

Key characteristics

Sharpe Ratio

MRNA:

-0.91

JNJ:

-0.35

Sortino Ratio

MRNA:

-1.39

JNJ:

-0.41

Omega Ratio

MRNA:

0.83

JNJ:

0.95

Calmar Ratio

MRNA:

-0.60

JNJ:

-0.30

Martin Ratio

MRNA:

-1.32

JNJ:

-0.89

Ulcer Index

MRNA:

42.08%

JNJ:

5.96%

Daily Std Dev

MRNA:

60.89%

JNJ:

15.20%

Max Drawdown

MRNA:

-92.39%

JNJ:

-52.60%

Current Drawdown

MRNA:

-91.83%

JNJ:

-16.33%

Fundamentals

Market Cap

MRNA:

$15.69B

JNJ:

$352.50B

EPS

MRNA:

-$5.81

JNJ:

$6.06

PEG Ratio

MRNA:

0.00

JNJ:

0.88

Total Revenue (TTM)

MRNA:

$5.08B

JNJ:

$87.70B

Gross Profit (TTM)

MRNA:

$3.35B

JNJ:

$60.56B

EBITDA (TTM)

MRNA:

-$2.07B

JNJ:

$29.51B

Returns By Period

In the year-to-date period, MRNA achieves a -60.22% return, which is significantly lower than JNJ's -5.50% return.


MRNA

YTD

-60.22%

1M

6.09%

6M

-70.57%

1Y

-54.10%

5Y*

14.85%

10Y*

N/A

JNJ

YTD

-5.50%

1M

-5.40%

6M

-1.32%

1Y

-3.36%

5Y*

2.47%

10Y*

5.90%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MRNA vs. JNJ - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Johnson & Johnson (JNJ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MRNA, currently valued at -0.91, compared to the broader market-4.00-2.000.002.00-0.91-0.35
The chart of Sortino ratio for MRNA, currently valued at -1.39, compared to the broader market-4.00-2.000.002.004.00-1.39-0.41
The chart of Omega ratio for MRNA, currently valued at 0.83, compared to the broader market0.501.001.502.000.830.95
The chart of Calmar ratio for MRNA, currently valued at -0.60, compared to the broader market0.002.004.006.00-0.60-0.30
The chart of Martin ratio for MRNA, currently valued at -1.32, compared to the broader market0.0010.0020.00-1.32-0.89
MRNA
JNJ

The current MRNA Sharpe Ratio is -0.91, which is lower than the JNJ Sharpe Ratio of -0.35. The chart below compares the historical Sharpe Ratios of MRNA and JNJ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00JulyAugustSeptemberOctoberNovemberDecember
-0.91
-0.35
MRNA
JNJ

Dividends

MRNA vs. JNJ - Dividend Comparison

MRNA has not paid dividends to shareholders, while JNJ's dividend yield for the trailing twelve months is around 3.42%.


TTM20232022202120202019201820172016201520142013
MRNA
Moderna, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
JNJ
Johnson & Johnson
3.42%3.00%2.52%2.45%2.53%2.57%2.74%2.38%2.73%2.87%2.64%2.83%

Drawdowns

MRNA vs. JNJ - Drawdown Comparison

The maximum MRNA drawdown since its inception was -92.39%, which is greater than JNJ's maximum drawdown of -52.60%. Use the drawdown chart below to compare losses from any high point for MRNA and JNJ. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-91.83%
-16.33%
MRNA
JNJ

Volatility

MRNA vs. JNJ - Volatility Comparison

Moderna, Inc. (MRNA) has a higher volatility of 18.88% compared to Johnson & Johnson (JNJ) at 4.35%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than JNJ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%JulyAugustSeptemberOctoberNovemberDecember
18.88%
4.35%
MRNA
JNJ

Financials

MRNA vs. JNJ - Financials Comparison

This section allows you to compare key financial metrics between Moderna, Inc. and Johnson & Johnson. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab